How Has the Syphilis Immunoassay Diagnostics Market Size Evolved in Recent Years?
The syphilis immunoassay diagnostics market has seen considerable growth due to a variety of factors.
• The syphilis immunoassay diagnostics market has expanded significantly in recent years. It will increase from $31.25 billion in 2024 to $33.76 billion in 2025, at a CAGR of 8.0%.
Contributing factors include the rising prevalence of STDs, a growing number of unidentified sexual encounters, increased cases of syphilis, government health initiatives, and a stronger focus on early disease detection.
What Is The Forecast For The Syphilis Immunoassay Diagnostics Market Size?
The syphilis immunoassay diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• The syphilis immunoassay diagnostics market is expected to grow significantly, reaching $45.42 billion by 2029 at a CAGR of 7.7%.
This growth can be attributed to the expanding high-risk population, increased awareness of partner notification programs, a rise in syphilis prevalence, growing awareness of syphilis diagnostics, and increased government healthcare spending. Key trends include the adoption of innovative technologies, rapid point-of-care tests, home test kits, advancements in laboratory testing methods, and the expansion of diagnostic laboratory techniques.
What Are The Essential Drivers Behind The Growth Of The Syphilis Immunoassay Diagnostics Market?
The surge in sexually transmitted infections (STIs) is anticipated to drive the growth of the syphilis immunoassay diagnostics market. These infections, also known as sexually transmitted diseases (STDs), primarily spread through sexual activity, including vaginal, anal, and oral sex. The escalation in sexually transmitted diseases is often accredited to reduced condom use, resistance to antibiotics, deficiencies in sexual education, social and behavioural shifts, stigma, diminished funding for STD programs, and increased travel. Syphilis immunoassay diagnostics play a crucial role in detecting and managing these diseases by delivering accurate and prompt identification of syphilis infection, which in turn facilitates suitable treatment and preventive measures. For example, a report by the Terrence Higgins Trust, a UK-based entity, revealed that the UK Health Security Agency (UKHSA) had registered 401,800 STIs in England in 2023, showing a 5% increase from the previous year. Thus, the surge in sexually transmitted diseases is a key driver of the syphilis immunoassay diagnostics market.
How Is The Global Syphilis Immunoassay Diagnostics Market Divided Into Key Segments?
The syphilis immunoassay diagnostics market covered in this report is segmented –
1) By Product: Analyzers, Reagents, Kits, Other Products
2) By Technology: Chemiluminescence Immunoassay (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Other Technologies
3) By Application: Men, Women
4) By End-User: Hospitals, Blood Banks, Diagnostics Labs, Other End-Users
Subsegments:
1) By Analyzers: Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers
2) By Reagents: Enzyme-Linked Immunosorbent Assay Reagents, Chemiluminescent Immunoassay Reagents, Rapid Plasma Reagin Reagents, Treponemal and Non-Treponemal Reagents
3) By Kits: ELISA Kits, Rapid Diagnostic Test Kits, CLIA Kits, Point-Of-Care Test Kits
4) By Other Products: Control and Calibration Materials, Sample Collection Devices, Ancillary Testing Accessories
Pre-Book The Syphilis Immunoassay Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Syphilis Immunoassay Diagnostics Market?
Significant firms in the syphilis immunoassay diagnostics market are striving to innovate and provide novel solutions like quick syphilis tests to bolster the detection accuracy and efficiency of syphilis. These rapid tests are convenient, efficient tools used at the point of care that can identify antibodies of syphilis in the body's fluids or blood within minutes, paving way for immediate diagnosis and earlier treatment. Chembio Diagnostics Inc., an infectious diseases-focused point-of-care diagnostics company from the U.S., procured a CLIA waiver from the FDA for its DPP HIV-Syphilis System in February 2023. This is a dual rapid test conceptualized for the simultaneous detection of antibodies to both HIV 1/2 and Treponema pallidum, the syphilis-causing bacteria. Aiming to enhance diagnosis and treatment, this rapid test that takes only 15 minutes could potentially minimize the risk of HIV among syphilis patients and notably curb mother-to-child syphilis transmission.
Who Are the Key Players In The Syphilis Immunoassay Diagnostics Market?
Major companies operating in the syphilis immunoassay diagnostics market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Siemens Healthineers
• Becton Dickinson and Company
• bioMérieux SA
• Bio-Rad Laboratories Inc.
• Meril Life Sciences Pvt. Ltd.
• Randox Laboratories Ltd.
• SEKISUI Diagnostics
• Bloodworks Northwest
• LetsGetChecked
• Everlywell Inc.
• ACON Laboratories Inc.
• Trinity Biotech
• Fujirebio
• CTK Biotech Inc.
• bioLytical Laboratories Inc.
• AdvaCare Pharma
• MyBioSource.com
• Gold Standard Diagnostics Frankfurt GmbH
• Newmarket Biomedical Ltd
• InTec PRODUCTS INC.
• NuGenerex Diagnostics LLC
What Are The Regional Insights Into The Syphilis Immunoassay Diagnostics Market?
North America was the largest region in the syphilis immunoassay diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the syphilis immunoassay diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
